The prognosis of patients with recurrent or persistent ovarian clear cell carcinoma: Results from a randomized phase III study (JGOG3017/GCIG)

The prognosis of patients with recurrent or persistent ovarian clear cell carcinoma: Results from a randomized phase III study (JGOG3017/GCIG) - JGOG 3017A1

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000035764

Enrollment

166

Registered

2019-02-04

Start date

2018-06-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

recurrent or persistent ovarian clear cell carcinoma

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: The JGOG3017/GCIG Trial was the randomized phase 3 study to compare paclitaxel plus carboplatin (TC) versus CPT-11 plus cisplatin (CPT-P) for 667 patients with stage 1 to 4 CCC. However, forty-three patients (6.4%) were ineligible due to non CCC histology, four withdrew from the study, and one was duplicated. A total of 619 patients with CCC were eligible for inclusion. Among 619 patients with CCC, 166 patients, excluding dead of disease without recurrence, had recurrent or persistent CCC.

Exclusion criteria

Exclusion criteria: However, forty-three patients (6.4%) were ineligible due to non CCC histology, four withdrew from the study, and one was duplicated.

Design outcomes

Primary

Measure	Time frame
The primary endpoint was to examine PPS of patients with recurrent CCC.	—

Countries

Japan

Contacts

Public ContactEiji Kondo

Mie university hospital Obstetrics and Gynecology

eijikon@clin.medic.mie-u.ac.jp0592230737

Outcome results